title: Identification of Patients Who Benefit From Bevacizumab in High-Grade Glioma-An Easy Question Turned Difficult: Treat the Scan or the Patient?
authors.affiliation: Northwestern University Feinberg School of Medicine, Chicago, IL tkruser@nm.org.
authors.forename: Tim J
authors.initials: TJ
authors.lastname: Kruser
authors.affiliation: University of Maryland School of Medicine, Baltimore, MD.
authors.forename: Minesh P
authors.initials: MP
authors.lastname: Mehta
authors.affiliation: Mercy Medical Center, Janesville, WI.
authors.forename: Kevin R
authors.initials: KR
authors.lastname: Kozak
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use*; D000068258:Bevacizumab / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000401:mortality* / Q000628:therapy*; D059248:Chemoradiotherapy; D003606:Dacarbazine / Q000031:analogs & derivatives*; D005260:Female; D005909:Glioblastoma / Q000188:drug therapy* / Q000401:mortality* / Q000628:therapy*; D006801:Humans; D008297:Male; D011788:Quality of Life
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D018906:Antineoplastic Agents, Alkylating; D000068258:Bevacizumab; D003606:Dacarbazine